- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.